Using chromogranin (CG) immunohistochemical staining, the prognostic significance of endocrine differentiation was investigated in 212 patients with primary colorectal adenocarcinoma (including 6 patients with mucosal carcinoma). CG‐immunoreactive cells were found to be an integral component of the tumor in 67 of 206 patients (32.5%, excluding mucosal carcinoma). The intra‐cellular localization of CG in the CG‐immunoreactive cells in cancer tissue was completely different from that in the normal endocrine cells of the large bowel. In addition, morphologic changes such as nuclear hyperchromasia and pleomorphism also indicated that the CG‐immunoreactive cells in the cancer tissue were malignant. The tumors were divided into three groups based on the frequency of CG‐immunoreactive cells: Group I (n = 139), negative; Group II (n = 38), less than 1 positive cell/mm2; and Group III (n = 29), more than 1 positive cell/mm2. No correlation was observed between CG‐immunoreactivity (CG‐IR) and tumor location, grade, depth of invasion, or stage, regardless of lymph node involvement. However, patients with numerous endocrine tumor cells (Group III) had a significantly worse prognosis compared with patients without endocrine cells (Group I) (multivariate Cox's model, P < 0.01). Similar findings were observed in patients with node‐negative tumor (multivariate Cox's model, P < 0.05). These results indicated that the neuroendocrine differentiation is an independent prognostic factor and that CG‐immunohistochemistry is useful for detecting a subgroup with a worse prognosis among patients with colorectal cancer.
ABSTRACT. Fifty-four canine cutaneous mast cell tumors were evaluated immunohistochemically for the expression of P-glycoprotein (PGP) and multidrug-resistance-associated protein (MRP). All tumors examined were graded according to the histological malignancy, ranging from grade I to III. The expression of PGP was confirmed in 15% (8/54) of whole, 33% (5/15) of grade I, 10% (3/31) of grade II, and 0% (0/8) of grade III tumors. The expression of MRP was found in 18% (10/54) of whole, 26% (4/15) of grade I, 19% (6/31) of grade II, and 0% (0/8) of grade III tumors. The cases positive to at least one of these 2 multidrug markers were 26%, 47%, 23% and 0% of whole and grade I to III tumors, respectively. These results indicate that at least 26% of canine cutaneous mast cell tumors express PGP and/or MRP and that these tumors may be resistant to several anti-cancer drugs. KEY WORDS: canine, mast cell tumor, multidrug resistance.
Most anesthetics have an immuno-suppressive effect on cellular and neurohumoral immunity,
and research shows that total intravenous anesthesia (TIVA) with propofol has a greater
immuno-protective effect than inhalational anesthesia in human medicine. However, in
veterinary clinics, these effects remain ambiguous. To clarify the details, we focused on
propofol and isoflurane, investigating clinical blood hematology and immunological
profiles drawn from healthy dogs under and after two anesthesia techniques. Twelve healthy
adult beagles were included in this study, randomly assigned to the propofol anesthesia
group (group P: n=6) or the isoflurane anesthesia group (group I: n=6). In both groups,
the number of lymphocytes in peripheral blood decreased after 2 hr of anesthesia (2 hr),
but group P showed significantly less decrease than group I. For T-lymphocyte subsets
examined by flowcytometry, the ratio of CD3+, CD4+ and CD8+ lymphocytes in the peripheral
blood mononuclear cell (PBMC) of group P at 2 hr also exhibited a high level compared to
group I. Moreover, for mRNA expression of cytokines measured by real-time PCR, the IL2
(pro-inflammatory cytokine) of group P showed no decrease like group I. The IL10
(anti-inflammatory cytokine) of group P also showed no increase like group I, while both
cytokines maintained nearly the same level until 2 hr. These results suggest that,
compared to propofol, isoflurane had more strongly immuno-suppression caused by
anesthesia, and propofol itself might have some immuno-protective effects. Thus, TIVA with
propofol might benefit immunological support in the perioperative period of dogs.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.